End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.84 CAD | +9.09% | -16.00% | +229.41% |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
- The stock, which is currently worth 2024 to 0.55 times its sales, is clearly overvalued in comparison with peers.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company is highly valued given the cash flows generated by its activity.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+229.41% | 173M | - | ||
+14.32% | 2.88B | D+ | ||
+13.95% | 1.75B | - | ||
+98.52% | 678M | - | ||
+3.18% | 478M | - | ||
+5.60% | 112M | - | ||
+0.28% | 99.47M | - | - | |
+44.94% | 58.59M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- HITI Stock
- HITI Stock
- Ratings High Tide Inc.